MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Psoriasis: Treatment and Pathogenesis
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,393 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,393 works in the cohort · of 4,299,418page 45 of 48

Labels cover 8 of 2,393 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,393 of 2,393 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
LB1475 The immune-phenotype of small plaque psoriasis
Touraj Khosravi‐Hafshejani, M. Ghoreishi, Michal Martinka, Richard I. Crawford, Jan Dutz
2018· article· en· Journal of Investigative Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
0
citations
affunlabeled
P77 Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, vs. placebo and apremilast in moderate-to-severe plaque psoriasis: achievement of absolute Psoriasis Area and Severity Index thresholds in two phase III trials
Richard B. Warren, Mark Lebwohl, Melinda Gooderham, Diamant Thaçi, Peter Foley, Alice B. Gottlieb +4 more
2023· article· en· British Journal of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
081 Granzyme K: A potential mediator of psoriasis
Katlyn C. Richardson, Christopher T. Turner, Sho Hiroyasu, Richard I. Crawford, Angela Burleigh, David J. Granville
2020· article· en· Journal of Investigative Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Efficacité et tolérance du risankizumab chez les patients adultes atteints de psoriasis en plaques modéré à sévère avec atteintes palmo-plantaires non pustuleuses : variations des scores PPASI et PASI dans l’étude de phase 3b IMMprint
M.G. Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle T. Pelle, B.P. Glick, Mar Llamas‐Velasco +6 more
2024· article· fr· Annales de Dermatologie et de Vénéréologie - FMC· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Caractéristiques à l’inclusion et résultats intermédiaires du mNAPSI à 12 mois de patients atteints de psoriasis en plaques modéré à sévère et de psoriasis unguéal concomitant sous traitement biologique dans l’étude Psoriasis Study of Health Outcomes
Alexander Egeberg, Andreas Pinter, Ronald Vender, S. Zaheri, Alan Brnabic, Christopher Schuster +5 more
2023· article· fr· Annales de Dermatologie et de Vénéréologie - FMC· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Efficacité du risankizumab chez les patients psoriasiques naïfs de biothérapies ou précédemment traités par biothérapies participant à l’étude VALUE, étude internationale observationnelle post-AMM
Diamant Thaçi, Mamitaro Ohtsuki, Julia‐Tatjana Maul, A. Szegedi, Paula Carolina Luna, Ronald Vender +5 more
2023· article· fr· Annales de Dermatologie et de Vénéréologie - FMC· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Pityriasis Alba
Markus Braun‐Falco, Henry J. Mankin, Sharon L. Wenger, Stephan DiSean Kendall, Gerard C. Blobe, Christoph K. Weber +183 more
2009· book-chapter· en· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
afffundno abstractunlabeled
Response to Potestio et al., “Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review”
Siddhartha Sood, Alexander Rimke, Brian D. Rankin, Abrahim Abduelmula, Jorge R. Georgakopoulos, Khalad Maliyar +6 more
2025· letter· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About